Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29249732 | 0.72 | — | — | |
| SCHEMBL29249731 | 0.64 | ALDH1A1 (0.38) | CYP1A2CYP3A4ALDH1A1CYP2A6LMNA | |
| SCHEMBL29249727 | 0.64 | CYP2A6 (0.38) | CYP1A2CYP3A4ALDH1A1CYP2A6LMNA | |
| SCHEMBL74389 | 0.63 | KIF11 (0.61) | KIF11CYP1A2CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL29583584 | 0.63 | KIF11 (0.61) | KIF11CYP1A2CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL13551946 | 0.63 | KDM4E (0.46) | KIF11CYP1A2CYP3A4ALDH1A1CYP2A6 | |
| SCHEMBL29249746 | 0.63 | — | — | |
| SCHEMBL27996644 | 0.61 | CYP19A1 (0.57) | KIF11CYP1A2CYP3A4ALDH1A1CYP2A6 | |
| SCHEMBL12622242 | 0.60 | NAPRT (0.57) | KIF11ALDH1A1TDP1KDM4ETP53 | |
| SCHEMBL21738715 | 0.60 | KIF11 (0.39) | KIF11CYP1A2CYP3A4ALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139600-A1 | 2-pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL CO., LTD. | 2003-07-24 | — | — | US | disclosed |
| US-6548673-B1 | Alkylation using transition metal complex catalyst; purified by acid/base extraction | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-15 | — | — | US | disclosed |
| US-6531602-B2 | Desilylation of a 2-pyridylsilane to form an alcohol | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-11 | — | — | US | disclosed |
| US-20020165397-A1 | 2-Pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL CO., LTD. | 2002-11-07 | — | — | US | disclosed |
| EP-1035125-A2 | 2-Pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165397-A1 | 2-Pyridylsilane, processes for producing and using the same | H1-0, RIOK2, H1-4 | KIF11 1481/4885CYP1A2 363/4885CYP3A4 178/4885 |
| US-20030139600-A1 | 2-pyridylsilane, processes for producing and using the same | H1-0, H1-4, H1-2 | KIF11 1420/4885CYP1A2 390/4885CYP3A4 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.